Healthcare Industry News: HSMN NewsFeed
News Release - August 31, 2021
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome linersLONDON, Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces it will showcase meaningful new material evidence for its OR3O Dual Mobility Hip System and OXINIUM DH Technology at the American Academy of Orthopedic Surgeons (AAOS) 2021 Annual Meeting in San Diego, CA. New data confirms a reduction in material loss and corrosion for OXINIUM DH (Diffusion Hardened) liners used with the OR3O System – an improvement on equivalent CoCr dual mobility liners within the test.1
In-vitro testing showed a substantial (p <0.05) difference in total volume metal ion elution between Cobalt Chromium Molybdenum (CoCrMo) modular acetabular liners and the OXINIUM DH liner used in the OR3O System.1 This is the first device-level testing comparing the performance of the OR3O Dual Mobility Liners against CoCrMo Liners- the only other material option available in the US market today. In recent literature, these CoCrMo implants have exhibited the potential limitations of metal ion elution,2,3,4 corrosion potential5 and mal-seating of implants6.
The benefits of OXINIUM femoral heads have been well documented in literature and global registries and this early testing provides further evidence to support its clinical use for wider applications such as dual mobility7,8,9. The authors conclude that, "DH-OXZr (OXINIUM DH) has been shown to reduce material loss and corrosion in femoral head tapers based on in-vitro testing, but this is the first study to show the potential benefits for these DH-OXZr acetabular liners.1"
"Modular dual mobility is here to stay, with the only caveat being the materials - in particular the CoCrMo liner design. That's why OR3O has been such a great option - we get the stability benefits of dual mobility and also OXINIUM DH to eliminate those material concerns," said Dr. George Guild III of Atlanta, GA. "This type of testing reaffirms my reasoning for using Smith & Nephew's OR3O Dual Mobility System."
The OR3O Dual Mobility System was launched in 2019 and has quickly transformed the modular dual mobility market segment due to its use of OXINIUM DH in lieu of traditional CoCrMo liner options. It is the only fully advanced bearing modular dual mobility option available in a segment that has grown to encompass 12% of primary hip replacements and 30% of hip revisions in the US.
"We continue to research, test, and learn about our technologies as is proven by this latest publication," said Vasant Padmanabhan, President R&D at Smith & Nephew. "OR3O has been an absolute game changer by offering OXINIUM DH and these results provide further evidence that it can be a competitive differentiator in this fast-growing market segment."
To learn more about the OR3O Dual Mobility Hip System and OXINIUM DH Technology, please stop by the Smith & Nephew booth (#1735) during AAOS 2021.
- Woodard E, Rister D. Accelerated Fretting and Corrosion Testing of Diffusion Hardened Oxidized Zirconium and Cobalt Chromium Molybdenum Modular Acetabular Liners. ORS 2021 Annual Meeting Paper No. 1629-LB.
- Nam D, Salih R, Nahhas CR, Barrack RL, Nunley RM. Is a modular dual mobility acetabulum a viable option for the young, active total hip arthroplasty patient? Bone Joint J. 2019;101-b:365–71. mobility liners Bone Joint J 2020;102-B(7 Supple B):20–26.
- Matsen Ko LJ, Pollag KE, Yoo JY, Sharkey PF. Serum metal ion levels following total hip arthroplasty with modular dual mobility components. J Arthroplasty. 2016;31:186–89
- Civinini R, Cozzi Lepri A, Carulli C, Matassi F, Villano M, Innocenti M. Patients following revision total hip arthroplasty with modular dual mobility components and cobalt-chromium
- Spece H, MacDonald DW, Mont MA, Lee G-C, Kurtz SM, Kurtz SM. Fretting corrosion and polyethylene damage mechanisms in modular dual mobility total hip arthroplasty. In: Mihalko W, Lemons J, Greenwald A, et al., eds. Beyond the implant: retrieval analysis methods for implant surveillance. West Conshohocken, PA: ASTM International. 2018:106–17.
- Romero J, Wach A, Silberberg S, Chiu Y-F, Westrich G, Wright T.M, Padgett D.E. 2020 Otto Aufranc Award: Malseating of modular dual mobility liners Bone Joint J 2020;102-B(7 Supple B):20–26.
- Davis ET, Pagkalos J, Kopjar B. Bearing surface and survival of cementless and hybrid total hip arthroplasty in the National Joint Registry of England,Wales, Northern Irestrom MPG."Do oxidized zirconium heads decrease tribocorrosion in total hip arthroplasty."Bone Joint J 101-B, 2019, 386–389
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2020 Annual Report, Adelaide; AOA, 2020: 1-474. Available at: https://aoanjrr.sahmri.com/annual-reports-2020.
- Hampton, C; Weitzler, L; Baral, E; Wright TM; Bostrom MPG."Do oxidized zirconium heads decrease tribocorrosion in total hip arthroplasty."Bone Joint J 101-B, 2019, 386–389.
Smith & Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith & Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms 'Group' and 'Smith & Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
Smith & Nephew expands its leading WEREWOLF(TM) Technology into total joint arthroplasty with launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand